Title:
Combined therapy
Document Type and Number:
Japanese Patent JP6087836
Kind Code:
B2
Abstract:
The invention relates to pharmaceutical compositions comprising: (a) at least one angiotensin receptor blocker or a pharmaceutically acceptable salt thereof, and (b) at least one chemokine receptor pathway inhibitor or a pharmaceutically acceptable salt thereof. The invention also relates to pharmaceutical compositions comprising: (a) at least one angiotensin receptor blocker or a pharmaceutically acceptable salt thereof; and (b) at least one chemokine receptor pathway inhibitor or a pharmaceutically acceptable salt thereof which inhibits a component of the chemokine receptor pathway other than the chemokine receptor. Oral sustained release pharmaceutical compositions comprising the pharmaceutical composition, as well as injectable sustained release pharmaceutical compositions comprising the pharmaceutical composition are described. The invention further relates to tablets, capsules, injectable suspensions, and compositions for pulmonary or nasal delivery comprising the pharmaceutical composition. Also described are: methods for assessing the efficacy of the pharmaceutical composition; methods for assessing the inhibition or partial inhibition activity of the pharmaceutical composition; methods for the treatment, amelioration or prevention of a condition or disease comprising administering to a subject a therapeutically effective amount of the pharmaceutical composition; and the use of the pharmaceutical composition for the manufacture of a dosage form for the treatment of a disease.
Inventors:
Pflegger, Kevin Donald George
McCarl, Elizabeth
Williams, James
McCarl, Elizabeth
Williams, James
Application Number:
JP2013547780A
Publication Date:
March 01, 2017
Filing Date:
January 11, 2012
Export Citation:
Assignee:
Dimerix Bioscience Proprietary Limited
International Classes:
A61K31/4184; A61K9/10; A61K9/20; A61K9/72; A61K31/80; A61P13/12; A61P43/00
Domestic Patent References:
| JP2010540527A |
Other References:
ATKINS, Robert C. et al,Proteinuria Reduction and Progression to Renal Failure in PatientsWith Type 2 Diabetes Mellitus and Overt Nephropathy,American Journal of Kidney Diseases,2005年,Vol.45, No.2 ,p.281-287
KANAMORI, Hiroshi et al,Inhibition of MCP-1/CCR2 pathway ameliorates the developmentof diabetic nephropathy,Biochemical and Biophysical Research Communications,2007年,Vol.360, No.4,p.772-777
MAJOR, Terry C. et al,A CCR2/CCR5 Antagonist Attenuates an Increase in Angiotensin II-Induced CD11b+ Monocytes from Atherogenic ApoE-/- Mice,Cardiovascular Drugs and Therapy,2009年,Vol.23, No.2,p.113-120
KANAMORI, Hiroshi et al,Inhibition of MCP-1/CCR2 pathway ameliorates the developmentof diabetic nephropathy,Biochemical and Biophysical Research Communications,2007年,Vol.360, No.4,p.772-777
MAJOR, Terry C. et al,A CCR2/CCR5 Antagonist Attenuates an Increase in Angiotensin II-Induced CD11b+ Monocytes from Atherogenic ApoE-/- Mice,Cardiovascular Drugs and Therapy,2009年,Vol.23, No.2,p.113-120
Attorney, Agent or Firm:
Ryoichi Takaoka
Nao Oda
Nao Oda
Previous Patent: A lighting installation which has a polymers content base material
Next Patent: ABSORPTION APPARATUS OF GASEOUS CARBON DIOXIDE
Next Patent: ABSORPTION APPARATUS OF GASEOUS CARBON DIOXIDE